Risk Factor Modification in CCR. How does CR work?

Slides:



Advertisements
Similar presentations
The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
Advertisements

JNC 8 Guidelines….
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
New (U.S.) Lipid Guidelines (The Good and Bad) Robert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver Disclosures: National Coordinator.
CVD risk estimation and prevention: An overview of SIGN 97.
Lipid Disorders and Management in Diabetes
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Benefits of intensive multiple risk factor intervention.
Rimoldi SF et al. J Clin Hypertens (Greenwich). 2015;17(3): Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive.
Special Diabetes Program for Indians Competitive Grant Program SPECIAL DIABETES PROGRAM FOR INDIANS Competitive Grant Program Clinical Goals for the Healthy.
Arteriosclerosis By: Timothy Granter & Megan Heath.
Lancet : doi: /S (08)60104-X Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from.
Cardiac rehabilitation Ahmad Osailan. What is cardiac rehabilitation is a sum of coordinated interventions required to ensure best physical, psychological.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
Orlando, Florida – October 7, 2011 Cardiac Rehab: Improving Outcomes One Step at a Time Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine.
Cardiovascular Disease in Women Module VII: Evidence-Based Guidelines.
Establishing Preventive Cardiology Programs Nathan Wong Nathan Wong.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Global impact of ischemic heart disease World Heart Federation, 2011.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
Recent Advances in Preventive Cardiology and Lifestyle Medicine Barry A. Franklin, Ph.D., FAHA Beaumont Health System Royal Oak, Michigan
RISK FACTOR FOR CORONARY ARTERY DISEASE
KORIN M. TRUMPIE Evidence Based Medicine Spring 2009.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Nursing Management of Clients with Stressors of Circulatory Function HYPERTENSION NUR133 LECTURE # 10 K. Burger MSEd,MSN, RN, CNE.
1 NHLBI/NEI National Institutes of Health NHLBI/NEI National Institutes of Health.
Cardiac Rehabilitation – The Evidence Base & Implications for Practice Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham.
Evidence-Based Medicine Summarizing Evidence Component 2 / Unit 5 1 Health IT Workforce Curriculum Version 1.0 /Fall 2010.
CardioVascular Disease Prevention. CVD prevention ‘The evidence that most cardiovascular disease is preventable continues to grow.’ ‘The evidence that.
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.
Chapter 15 Cardiovascular Disease Risk Factors and Physical Activity.
 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Innovations in Management of Cardiovascular Disease for Global Health
Collaborative Atorvastatin Diabetes Study CARDS Dr Sachin Kadoo.
Polypill x Aspirin Project Groups 3 and 4
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
ASSOCIATED CONDITIONS WITH DIABETES MELLITUS TYPE II.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Case 2: Dyslipidaemia in Type 2 Diabetes Mellitus.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
 In 2003, the USPSTF recommended that clinicians screen adults for obesity and offer intensive counseling and behavioral interventions to promote weight.
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Management of Obesity in Diabetes Key Messages An estimated 80 to 90% of persons with type 2 diabetes are overweight or obese. A modest weight loss of.
Date of download: 9/17/2016 From: Effectiveness of Primary Care–Relevant Treatments for Obesity in Adults: A Systematic Evidence Review for the U.S. Preventive.
Blood Pressure and Lipid Trials: Rationale, Importance and Design
Noncommunicable Diseases Surveillance in Egypt
ACCORD Design and Baseline Characteristics
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Ungroup once.
Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals
The Anglo Scandinavian Cardiac Outcomes Trial
HDL cholesterol and cardiovascular risk Epidemiological evidence
First time a CETP inhibitor shows reduction of serious CV events
Risk factor thresholds: their existence under scrutiny
HDL cholesterol and cardiovascular risk
Diabetes Health Status Report
TNT: Baseline and final LDL cholesterol levels
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
How to Teach it?.
Description of studies for pooled analyses
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Goals & Guidelines A summary of international guidelines for CHD
PROSPER: trial design                                                                                                                                                                 
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Risk Factor Modification in CCR. How does CR work?

Outline Elements of CR Risk Factors Pharmacotherapy Exercise-based and Comprehensive CR as effective therapy –Mortality and Morbidity –Risk factor reduction

Outline Psychological Interventions as an adjunct to CCR Other potential ‘interventions’ –Things there aren’t (yet) drugs for: Psychosocial Effects QoL Functional capacity*

Comprehensive Model (CCR) Comprehensive Cardiac Rehabilitation Services Psychosocial/ Vocational Counselling Exercise Training Risk Factor Modification Medical Surveillance Emergency Support

Pharmacologically Modifiable Risk Factors High blood cholesterol –Statins High blood pressure –ACE-inhibitors, Ca+ channel inhibitors, beta-blockers Diabetes mellitus –Insulin Obesity and Overweight –Orlistat

‘Psychologically’ Modifiable Risk Factors (Lifestyle Factors) Smoking Physical inactivity Obesity and overweight* –Problems High blood cholesterol* –Problems Diabetes mellitus* –*Via diet therapy

Physiologically Modifiable Risk Factors High blood pressure High blood cholesterol Diabetes mellitus Obesity and overweight Physical inactivity* –Via lifestyle modificaiton

Efficacy of Pharmacological Interventions Meta-analytical level evidence available for mortality/risk factor reduction: –Statins, –Beta-blockers, –ACE-inhibitors, –Ca+ channel agonists

Efficacy of Pharmacological Interventions Meta-analytical level evidence available for alterations in: –Homocysteine Folic Acid B-6 & B-12 –Platelet Function Aspirin

Polypill anyone?

A strategy to reduce cardiovascular disease by more than 80% N J Wald, M R Law (2003)

Exercise only CR: Positive Outcomes for All cause mortality Total cardiac deaths Non-fatal MI, PTCA/CABG

Efficacy of Exercise-based Interventions Pooled Outcomes for Risk Factors

Comprehensive CR: Positive Outcomes for Total cardiac deaths Non-fatal MI, PTCA/CABG

Taylor et al Am J Med May 15;116(10):682-92

Significant Changes in Modifiable Risk Factors TC ( mmol/L; 95% CI: to mmol/L) TG (-0.23 mmol/L; 95% CI: to mmol/L SBP (-3.2 mm Hg; 95% CI: -5.4 to -0.9 mm Hg) Smoking (OR = 0.64; 95% CI: 0.50 to 0.83)

Modifiable Risk Factors Without Evidence of Change –LDL-C (-0.20 mmol/L; 95% CI: to 0.12 mmol/L –HDL-C (-0.05 mmol/L; 95% CI: to 0.14 mmol/L) –DBP (-1.18 mmHg; 95% CI: to 0.32) mmHg

Modifiable Risk Factors (cont) Health related quality of life (QoL): n=12 reviewed but no meta-analysis (high variation in methodology) General conclusion: –Improvement in QoL with CR but improvement also in controls (in 10/12 trials)

Discussion: Mortality & Morbidity Exercise-based CR works Little additional benefit from lifestyle management

Discussion: Risk Factors Evidence for exercise-based and comprehensive CR for –SBP (but not DBP) –Lipids? –QoL* *Not risk factor –Smoking Question: ‘Is there an additional benefit from psychological interventions in CCR’.

Efficacy of Psychological Interventions in CCR. Is there an additional benefit from psychological interventions in CCR’.

Efficacy of Psychological Interventions Pooled Outcomes for Clinical End Points

Efficacy of Psychological Interventions Pooled Outcomes for Risk Factor: Lipids

Efficacy of Psychological Interventions Pooled Outcomes for Risk Factor: Blood Pressure

Efficacy of Psychological Interventions Pooled Outcomes for Risk Factor: Smoking

Efficacy of Psychological Interventions Pooled Outcomes for Psychological Measures

Conclusions Strong evidence for pharmacological interventions Mortality Morbidity reduced with just exercise Additional effect of Exercise/CCR –Some lipids –Smoking –QoL?

Conclusions Additive effects of psych: –TC, LDL, SBP Additional effects of psych: –Anxiety? –Depression –HDL –DBP

Magic? Psychosocial effects difficult to quantify ‘Rub-off’ of being in a group Associated acitivities Magic.